- Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi REM, Corcione F. Worldwide burden of colorectal cancer: a
review. Updates Surg 2016; 68(1):7-11.
2. Marley AR, Nan H. Epidemiology of colorectal cancer. International journal of molecular epidemiology and genetics
2016;7(3):105-111.
3. Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. BioMed
Research International 2011;5: 1-19
4. Migheli F, Migliore L. Epigenetics of colorectal cancer. Clin Genet 2012;81(4):312-318.
5.Matsubara N. Epigenetic regulation and colorectal cancer. Dis Colon Rectum 2012;55(1):96-104.
6. Espada J, Esteller M. DNA methylation and the functional organization of the nuclear compartment. Seminars in cell
& developmental biology. 21. Elsevier; 2010:238-246.
7. Jia Y, Guo M. Epigenetic changes in colorectal cancer. Chin J Cancer 2013;32(1):21-28.
8. Samowitz WS. The CpG island methylator phenotype in colorectal cancer. The Journal of molecular diagnostics:
JMD 2007;9(3):281-289.
9. Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol
2007;20(7):711-721
10. Jair K-W, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen R-WC, et al. De novo CpG island methylation in human
cancer cells. Cancer Res 2006;66(2):682-692.
11. Copeland RA, Olhava EJ, Scott MP. Targeting epigenetic enzymes for drug discovery. Curr Opin Chem Biol
2010;14(4):505-510.
12. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and
therapies. Nature Reviews Cancer 2001;1(3):194-202.
13. Kawamata N, Inagaki N, Mizumura S, Sugimoto Kj, Sakajiri S, Ohyanagi‐Hara M, et al. Methylation status analysis
of cell cycle regulatory genes (p16INK4A, p15INK4B, p21Waf1/Cip1, p27Kip1 and p73) in natural killer cell
disorders. Eur J Haematol 2005;74(5):424-429.
14. Khatami F, Larijani B, Heshmat R, Keshtkar A, Mohammadamoli M, Teimoori-Toolabi L, et al. Meta-analysis of
promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer. PloS one.
2017;12(9): 0184892.
15. Hu X-T, He C. Recent progress in the study of methylated tumor suppressor genes in gastric cancer. Chinese
Journal of Cancer. 2013;32(1):31-41.
16. Radpour R, Barekati Z, Kohler C, Lv Q, Bürki N, Diesch C, et al. Hypermethylation of tumor suppressor genes
involved in critical regulatory pathways for developing a blood-based test in breast cancer. PloS one. 2011;6(1):16080.
17. Ozdemir F, Altinisik J, Karateke A, Coksuer H, Buyru N. Methylation of tumor suppressor genes in ovarian cancer.
Experimental and therapeutic medicine. 2012;4(6):1092-1096.
18. Zhao M, Sun J, Zhao Z. TSGene: a web resource for tumor suppressor genes. Nucleic acids research. 2013;41(D1):
970-976
19. Sanaei M, Kavoosi F. Effects of 5-aza-2ˈ-deoxycytidine and Valproic Acid on Epigenetic-modifying DNMT1 Gene
Expression, Apoptosis Induction and Cell Viability in Hepatocellular Carcinoma WCH-17 cell line. Iranian Journal of
Pediatric Hematology & Oncology 2019.
20. Sanaei M, Kavoosi F. Effect of 5-aza-2'-deoxycytidine in comparison to valproic acid and trichostatin A on histone
deacetylase 1, DNA methyltransferase 1, and CIP/KIP family (p21, p27, and p57) genes expression, cell growth
inhibition, and apoptosis induction in colon cancer SW480 cell line. Advanced biomedical research 2019;8: 52.
21. Sanaei M, Kavoosi F. Effect of DNA methyltransferase in comparison to and in combination with histone
deacetylase inhibitors on hepatocellular carcinoma HepG2 cell line. Asian Pacific journal of cancer prevention: APJCP
2019;20(4):1119.
22. Sanaei M, Kavoosi F, Valiani A, Ghobadifar MA. Effect of genistein on apoptosis and proliferation of
hepatocellular Carcinoma Hepa1-6 Cell Line. Int J Prev Med 2018;9: 12.
23. Sanaei M, Kavoosi F, Roustazadeh A, Golestan F. Effect of genistein in comparison with trichostatin a on
reactivation of DNMTs genes in hepatocellular carcinoma. Journal of clinical and translational hepatology
2018;6(2):141.
24. Velez AMA, Howard MS. Tumor-suppressor genes, cell cycle regulatory checkpoints, and the skin. N Am J Med
Sci 2015;7(5):176.
25. Cooper S. Checkpoints and restriction points in bacteria and eukaryotic cells. Bioessays 2006;28(10):1035-1039.
26. Molin S, Grgic M, Ruzicka T, Herzinger T. Silencing of the cell cycle checkpoint gene 14‐3‐3σ in basal cell
carcinomas correlates with reduced expression of IKK‐α. J Eur Acad Dermatol Venereol 2014;28(8):1113-1116.
27. Sherr CJ. Principles of tumor suppression. Cell 2004;116(2):235-46.
28. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001;20(24):3139-3155.
29. Mojarad EN, Kuppen PJ, Aghdaei HA, Zali MR. The CpG island methylator phenotype (CIMP) in colorectal
cancer. Gastroenterology and hepatology from bed to bench 2013;6(3):120.
30. Sarabi MM, Naghibalhossaini F. Association of DNA methyltransferases expression with global and gene‐specific
DNA methylation in colorectal cancer cells. Cell Biochem Funct 2015;33(7):427-33.
31. Komata T, Kanzawa T, Takeuchi H, Germano I, Schreiber M, Kondo Y, et al. Antitumour effect of cyclindependent kinase inhibitors (p16 INK4A, p18 INK4C, p19 INK4D, p21 WAF1/CIP1 and p27 KIP1) on malignant
glioma cells. Br J Cancer 2003;88(8):1277-1280.
32.Jubb A, Bell S, Quirke P. Methylation and colorectal cancer. The Journal of pathology 2001;195(1):111-134.
33. Zhou Z, Zhang H, Lai J, Diao D, Li W, Dang C, et al. Relationships between p14ARF gene methylation and
clinicopathological features of colorectal cancer: a meta-analysis. PLoS One 2016;11(3): 1-8.
34. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, et al. Hypermethylation-associated
inactivation of p14ARF is independent of p16INK4a methylation and p53 mutational status. Cancer Res
2000;60(1):129-133.
35. Nilsson TK, Löf-Öhlin ZM, Sun X-F. DNA methylation of the p14ARF, RASSF1A and APC1A genes as an
independent prognostic factor in colorectal cancer patients. Int J Oncol 2013;42(1):127-133.
36. Ishiguro A, Takahata T, Saito M, Yoshiya G, Tamura Y, Sasaki M, et al. Influence of methylated p15 INK4b and
p16 INK4a genes on clinicopathological features in colorectal cancer. J Gastroenterol Hepatol 2006;21(8):1334-1339.
37. Coppedè F, Lopomo A, Spisni R, Migliore L. Genetic and epigenetic biomarkers for diagnosis, prognosis and
treatment of colorectal cancer. World journal of gastroenterology: WJG 2014;20(4):943.
38. Gagliardi G, Biricotti M, Failli A, Orsini G, Consolini R, Migheli F, et al, Spinelli C, Spisni R. Colorectal
carcinoma and folate. Ann Ital Chir 2013; 84:123-131.
39. Chen Y-Z, Liu D, Zhao Y-X, Wang H-T, Gao Y, Chen Y. Relationships between p16 gene promoter methylation
and clinicopathologic features of colorectal cancer: A meta-analysis of 27 cohort studies. DNA Cell Biol
2014;33(10):729-738.
40. Kim BN, Yamamoto H, Ikeda K, Damdinsuren B, Sugita Y, Ngan CY, et al. Methylation and expression of
p16INK4 tumor suppressor gene in primary colorectal cancer tissues. Int J Oncol 2005; 26(5):1217-1226.
41. Kim JH, Yoon SY, Kim C-N, Joo JH, Moon SK, Choe IS, et al. The Bmi-1 oncoprotein is overexpressed in human
colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004; 203(2):217-224.
42. Burri N, Shaw P, Bouzourene H, Sordat I, Sordat B, Gillet M, et al. Methylation silencing and mutations of the p14
ARF and p16 INK4a genes in colon cancer. Lab Invest 2001; 81 (2): 217-229.
43. Mitomi H, Fukui N, Tanaka N, Kanazawa H, Saito T, Matsuoka T, et al. Aberrant p16 INK4a methylation is a
frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity. J Cancer
Res Clin Oncol 2010; 136(2):323.
- 44. Esteller M, Gonzalez S, Risques R, Marcuello E, Mangues R, Germa J, et al. K-ras and p16 aberrations confer poor
prognosis in human colorectal cancer. J Clin Oncol 2001;19(2):299-304.
45. Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, et al. Molecular detection of p16 promoter
methylation in the serum of recurrent colorectal cancer patients. Int J Cancer 2003;105(4):491-493.
46. Hibi K, Nakayama H, Koike M, Kasai Y, Ito K, Akiyama S, et al. Colorectal cancers with both p16 and p14
methylation show invasive characteristics. Jap J Cancer Res 2002;93(8):883-887.
47. Quereda V, Porlan E, Cañamero M, Dubus P, Malumbres M. An essential role for Ink4 and Cip/Kip cell-cycle
inhibitors in preventing replicative stress. Cell Death Differ 2016;23(3):430-441.
48. Fang J-Y, Lu J, Chen Y-X, Yang L. Effects of DNA methylation on expression of tumor suppressor genes and
proto-oncogene in human colon cancer cell lines. World J Gastroenterol 2003;9(9):1976.
49. Fang JY, Chen YX, Juan L, Rong L, Li Y, Zhu HY, Gu WQ, et al. Epigenetic modification regulates both
expression of tumor-associated genes and cell cycle progressing in human colon cancer cell lines: Colo-320 and
SW1116. Cell Res 2004;14(3):217-226.
50. Zeng H, Yan L, Cheng W-H, Uthus EO. Dietary selenomethionine increases exon-specific DNA methylation of the
p53 gene in rat liver and colon mucosa. The Journal of nutrition 2011;141(8):1464-1468.
51. Suzuki H, Igarashi S, Nojima M, Maruyama R, Yamamoto E, Kai M, et al. IGFBP7 is a p53-responsive gene
specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis 2010;31(3):342-349.
52. Lam K, Pan K, Linnekamp JF, Medema JP, Kandimalla R. DNA methylation based biomarkers in colorectal cancer:
a systematic review. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 2016;1866(1):106-120.
53. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et al. DNA methylation patterns in
hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001;10(26):3001-3007.
54. Xu X-L, Yu J, Zhang H-Y, Sun M-H, Gu J, Du X, et al. Methylation profile of the promoter CpG islands of 31
genes that may contribute to colorectal carcinogenesis. World journal of gastroenterology: WJG 2004;10(23):3441.
55. Kim M, Chang X, Yamashita K, Nagpal J, Baek J, Wu G, et al. Aberrant promoter methylation and tumor
suppressive activity of the DFNA5 gene in colorectal carcinoma. Oncogene 2008;27(25):3624-3634.
56. Gan L, Chen S, Zhong J, Wang X, Lam EK, Liu X, et al. ZIC1 is downregulated through promoter
hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. PLoS One 2011;6(2): 17-24.
57. Bagci B, Sari M, Karadayi K, Turan M, Ozdemir O, Bagci G. KRAS, BRAF oncogene mutations and tissue specific
promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer
patients. Cancer Biomark 2016;17(2):133-143.
|
